Chan 2002.

Methods	3‐Week wash‐out period 6‐Week single‐centre randomised double‐blind placebo‐controlled study Evening doses
Participants	25 obese men from Australia recruited from the community with dyslipidaemia, mean age 52 years; TG > 1.2 mmol/L (106 mg/dL), TC > 5.2 mmol/L (201 mg/dL) 12 participants received placebo, 13 received atorvastatin Exclusion criteria: diabetes E2/E2 genotype, macroproteinuria; liver, renal dysfunction; hypothyroidism, CVD, > 30 g alcohol/d Placebo baseline TC: 5.82 mmol/L (225 mg/dL) Placebo baseline LDL‐C: 3.80 mmol/L (147 mg/dL) Placebo baseline HDL‐C: 1.05 mmol/L (41 mg/dL) Placebo baseline TG: 1.69 mmol/L (150 mg/dL) Atorvastatin baseline TC: 5.81 mmol/L (225 mg/dL) Atorvastatin baseline LDL‐C: 3.81 mmol/L (147 mg/dL) Atorvastatin baseline HDL‐C: 1.01 mmol/L (39 mg/dL) Atorvastatin baseline TG: 1.88 mmol/L (167 mg/dL)
Interventions	Placebo Atorvastatin 40 mg/d
Outcomes	Per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed WDAEs were not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information about sequence generation was provided to permit judgement of 'yes' or 'no'
Allocation concealment (selection bias)	Unclear risk	No information about allocation concealment was provided to permit judgement of 'yes' or 'no'
Blinding (performance bias and detection bias) All outcomes	Low risk	"Double‐blind, placebo‐controlled intervention"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	High risk	All lipid parameters were measured; withdrawals due to adverse events were not reported
Other bias	High risk	Pfizer partially funded the study; data may support bias for atorvastatin